American Century Companies Inc. Makes New $516,000 Investment in AtriCure, Inc. (NASDAQ:ATRC)

American Century Companies Inc. bought a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 16,872 shares of the medical device company's stock, valued at approximately $516,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Heck Capital Advisors LLC bought a new position in shares of AtriCure in the 4th quarter worth approximately $60,000. Venturi Wealth Management LLC increased its holdings in AtriCure by 1,337.6% during the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after buying an additional 2,100 shares during the last quarter. KBC Group NV raised its position in AtriCure by 65.3% in the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after acquiring an additional 932 shares during the period. R Squared Ltd purchased a new position in shares of AtriCure during the 4th quarter worth $89,000. Finally, AlphaQuest LLC grew its position in shares of AtriCure by 855.1% during the 4th quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company's stock valued at $155,000 after acquiring an additional 4,532 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Price Performance

Shares of ATRC stock traded down $0.26 during mid-day trading on Tuesday, hitting $32.36. The company had a trading volume of 398,359 shares, compared to its average volume of 664,988. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The stock's 50 day moving average price is $35.84 and its 200-day moving average price is $34.34. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $43.11. The company has a market capitalization of $1.58 billion, a P/E ratio of -34.06 and a beta of 1.65.

Remove Ads

Insiders Place Their Bets

In other news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.20% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on ATRC shares. Piper Sandler raised their target price on AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. lowered their price objective on AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, March 27th. JMP Securities reissued a "market outperform" rating and issued a $60.00 target price on shares of AtriCure in a report on Monday, February 10th. BTIG Research restated a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $51.00 price target on shares of AtriCure in a research report on Thursday, March 27th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $49.44.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.